


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~strikethrough~~ and additions are underlined.



1 - 3. (Cancelled)

4. (Previously presented) A pharmaceutical composition comprising; a compound represented by the following general formula (III), and a pharmaceutically acceptable salt or an isomer thereof:



wherein

X is selected from the group consisting of a hydroxyl group, -NHOH, -NHOCH<sub>2</sub>Ph, and



R is selected from the group consisting of a C1-C5 alkyl group, C2-C5 alkenyl group, C2-C5 alkynyl group, C3-C5 allyl group, a heterocyclic group and aromatic aryl group;

n is an integer of 1 to 5; and

dotted line (---) means double bond.

5. (Previously presented) The pharmaceutical composition of claim 4, wherein said R is selected from the group consisting of thiophenyl group, naphtyl group, pyrrolyl group, furyl group and biphenyl group.

6. (Previously presented) The pharmaceutical composition of claim 5, wherein said compound is selected from the group consisting of;

N-hydroxy-3-(1-naphthalene-2-ylmethyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,

N-hydroxy-3-(1-methyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,

3-(1-allyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-N-hydroxy-propionamide,

N-hydroxy-3-[1-(2-naphthalene-1-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

N-hydroxy-3-[2-oxo-1-(2-thiophen-2-yl-ethyl)-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,

3-[1-(3-biphenyl-4-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N-hydroxy-propionamide, and


N-hydroxy-3-[1-(3-naphthalene-2-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

7 - 20. (Canceled)



21. (Previously presented) The pharmaceutical composition of claim 6, wherein said compound is N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

22. (Canceled)

23. (Currently amended) A method of treatment for prostate cancer or ~~uterine~~ cervical cancer to produce a beneficial effect comprising; administering a compound represented by the following general formula (III), and a pharmaceutically acceptable salt or an isomer thereof, to a Mammal in need thereof,



wherein

X is selected from the group consisting of a hydroxyl group, -NHOH, -NHOCH<sub>2</sub>Ph,  and ;

R is selected from the group consisting of a C1-C5 alkyl group, C2-C5 alkenyl group, C2-C5 alkynyl group, C3-C5 allyl group, a heterocyclic group and aromatic aryl group;

n is an integer of 1 to 5; and

dotted line (---) means double bond.

24. (Previously presented) The method of Claim 23; wherein said R is selected from the group consisting of thiophenyl group, naphtyl group, pyrrolyl group, furyl group and biphenyl group.

25. (Previously presented) The method of Claim 24; wherein said compound is selected from the group consisting of;

N-hydroxy-3-(1-naphthalene-2-ylmethyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,  
N-hydroxy-3-(1-methyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,  
3-(1-allyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-N-hydroxy-propionamide,  
N-hydroxy-3-[1-(2-naphthalene-1-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,  
N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,  
N-hydroxy-3-[2-oxo-1-(2-thiophen-2-yl-ethyl)-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,  
3-[1-(3-biphenyl-4-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N-hydroxy-propionamide, and  
N-hydroxy-3-[1-(3-naphthalene-2-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

26. (Previously presented) The method of Claim 25; wherein said compound is N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

27 - 28. (Canceled)